Is Bloom Energy The Best Stock to Buy Now?
Shares of energy startup Bloom Energy (NYSE:BE) have advanced by…
Buy
71
APGE Quote, Financials, Valuation and Earnings
Last price:
$78.50
Seasonality move
:
86.09%
Day range:
$77.31 - $80.99
52-week range:
$26.20 - $80.99
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
--
P/B ratio:
9.15x
Volume:
2.8M
Avg. volume:
891.6K
1-year change:
67.04%
Market cap:
$5.4B
Revenue:
--
EPS (TTM):
-$4.32
Analysts' Opinion
-
Consensus RatingApogee Therapeutics, Inc. has received a consensus rating of Buy. The company's average rating is a Buy based on 13 Buy ratings, 0 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $96.85, Apogee Therapeutics, Inc. has an estimated upside of 23.31% from its current price of $78.54.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $70.00 representing 10.87% downside risk from its current price of $78.54.
Fair Value
-
According to the consensus of 13 analysts, Apogee Therapeutics, Inc. has 23.31% upside to fair value with a price target of $96.85 per share.
APGE vs. S&P 500
-
Over the past 5 trading days, Apogee Therapeutics, Inc. has overperformed the S&P 500 by 1.79% suggesting its relative strength compared to the major market average is strong at this time.
Share Buyback
-
Apogee Therapeutics, Inc. does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Apogee Therapeutics, Inc. has grown year-over-year revenues for 0 quarters straight. In the most recent quarter Apogee Therapeutics, Inc. reported revenues of --.
Earnings Growth
-
Apogee Therapeutics, Inc. has grown year-over-year earnings for 0 quarters straight. In the most recent quarter Apogee Therapeutics, Inc. reported earnings per share of -$1.11.
Enterprise value:
4.8B
EV / Invested capital:
8.13x
Price / LTM sales:
--
EV / EBIT:
--
EV / Revenue:
--
PEG ratio (5yr expected):
-0.31x
EV / Free cash flow:
-20.41x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
-$1.1M
Return On Assets:
-35.95%
Net Income Margin (TTM):
--
Return On Equity:
-38.09%
Return On Invested Capital:
-37.45%
Operating Margin:
--
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Income Statement | ||||||
| Revenue | -- | -- | -- | -- | -- | |
| Gross Profit | -- | -$113K | -$1.1M | -$48K | -$400K | |
| Operating Income | -$69.9M | -$178.1M | -$283.4M | -$58.7M | -$71.3M | |
| EBITDA | -$69.9M | -$178M | -$282.3M | -$58.6M | -$70.9M | |
| Diluted EPS | -$1.31 | -$2.73 | -$4.32 | -$0.86 | -$1.11 | |
| Period Ending | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2025-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | -- | -- | $426.2M | $534.5M | $540.1M | |
| Total Assets | -- | -- | $426.4M | $776.3M | $626.2M | |
| Current Liabilities | -- | -- | $17.2M | $32.6M | $34M | |
| Total Liabilities | -- | -- | $17.2M | $41.9M | $39.8M | |
| Total Equity | -- | -- | $409.2M | $734.4M | $586.3M | |
| Total Debt | -- | -- | -- | $9.3M | $5.8M | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$54.2M | -$133.2M | -$232.5M | -$42.5M | -$54.3M | |
| Cash From Investing | -- | -$620.7M | $155.4M | -$146.4M | $17.9M | |
| Cash From Financing | $474.1M | $450.5M | $65.9M | $383K | $19.7M | |
| Free Cash Flow | -$54.2M | -$134.5M | -$237.6M | -$43.3M | -$54.3M | |
APGE
Sector
Market Cap
$5.4B
$27.9M
Price % of 52-Week High
96.98%
51.04%
Dividend Yield
0%
0%
Shareholder Yield
-2.81%
-1.49%
1-Year Price Total Return
67.04%
-16.66%
Beta (5-Year)
--
0.516
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Buy
Level
$76.58
200-day SMA
Buy
Level
$44.81
Bollinger Bands (100)
Buy
Level
36.53 - 65.49
Chaikin Money Flow
Sell
Level
-1.5M
20-day SMA
Buy
Level
$73.79
Relative Strength Index (RSI14)
Buy
Level
71.57
ADX Line
Buy
Level
40.62
Williams %R
Sell
Level
-18.4072
50-day SMA
Buy
Level
$63.88
MACD (12, 26)
Buy
Level
4.19
25-day Aroon Oscillator
Buy
Level
96
On Balance Volume
Neutral
Level
17.6M
Financial Scores
Buy
Altman Z-Score
(Annual)
Level (42.7885)
Buy
CA Score
(Annual)
Level (-0.0957)
--
Beneish M-Score
(Annual)
Level (--)
Buy
Momentum Score
Level (5)
Sell
Ohlson Score
Level (6.5404)
--
Piotroski F Score
(Annual)
Level (--)
Sell
Quality Ratio Score
Level (1)
Buy
Fundamental Score
Level (4)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Apogee Therapeutics, Inc. operates as a biotechnology company. It offers treatment of atopic dermatitis (AD), chronic obstructive pulmonary disease (COPD) and related inflammatory and immunology (I&I) indications. The company was founded in 2022 and is headquartered in Waltham, MA.
Stock Forecast FAQ
In the current month, APGE has received 13 Buy ratings 0 Hold ratings, and 0 Sell ratings. The APGE average analyst price target in the past 3 months is $96.85.
-
Where Will Apogee Therapeutics, Inc. Stock Be In 1 Year?
According to analysts, the consensus estimate is that Apogee Therapeutics, Inc. share price will rise to $96.85 per share over the next 12 months.
-
What Do Analysts Say About Apogee Therapeutics, Inc.?
Analysts are divided on their view about Apogee Therapeutics, Inc. share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Apogee Therapeutics, Inc. is a Sell and believe this share price will drop from its current level to $70.00.
-
What Is Apogee Therapeutics, Inc.'s Price Target?
The price target for Apogee Therapeutics, Inc. over the next 1-year time period is forecast to be $96.85 according to 13 Wall Street analysts, 13 of them rate the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.
-
Is APGE A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Apogee Therapeutics, Inc. is a Buy. 13 of 13 analysts rate the stock a Buy at this time.
-
How Can I Buy Shares Of APGE?
You can purchase shares of Apogee Therapeutics, Inc. via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Apogee Therapeutics, Inc. shares.
-
What Is The Apogee Therapeutics, Inc. Share Price Today?
Apogee Therapeutics, Inc. was last trading at $78.50 per share. This represents the most recent stock quote for Apogee Therapeutics, Inc.. Yesterday, Apogee Therapeutics, Inc. closed at $78.54 per share.
-
How To Buy Apogee Therapeutics, Inc. Stock Online?
In order to purchase Apogee Therapeutics, Inc. stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
Get APGE Stock Alert
Signup to receive the latest stock alerts
Financial Ratios
APGE
Sector
P/E ratio
--
23.85x
PEG ratio
-0.31x
-0.01x
P/B ratio
9.15x
1.81x
Price / LTM sales
--
1.58x
Growth Metrics
APGE
Sector
Revenue growth
--
4.62%
Earnings growth
-28.18%
10.5%
Revenue (5-year growth)
--
6.5%
Earnings forecast
-$1.15
-$0.21
Profitability
APGE
Sector
Profitability FY 2024
-$189K
$3.6M
Return on invested capital
-37.45%
-31.87%
Return on assets
-35.95%
-28.18%
Return on equity
-38.09%
-37.63%
Earnings Date
Last Earnings Date
Nov
10
Next Earnings Date
Mar
2
Estimated Next Earnings Date
Feb
9
Balance Sheet
APGE
Sector
Total cash
$527.3M
$26.4M
Short term investments
$378.9M
$25.7M
Total assets
$754M
$76.9M
Long term debt
$5.8M
$3.4M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is Berkshire Hathaway Stock Undervalued?
Berkshire Hathaway (NYSE:BRK.A,BRK.B) has undershot the market this year, returning…
Is Oracle Stock Undervalued?
Shares of Oracle (NYSE:ORCL) rocketed higher earlier this year when…
Stock Ideas
Buy
54
Is NVDA Stock a Buy?
Market Cap: $4.4T
P/E Ratio: 62x
Buy
53
Is AAPL Stock a Buy?
Market Cap: $4T
P/E Ratio: 37x
Buy
57
Is GOOG Stock a Buy?
Market Cap: $3.7T
P/E Ratio: 38x
Alerts
Sell
1
LW alert for Dec 20
Lamb Weston Holdings, Inc. [LW] is down 25.96% over the past day.
Buy
54
BMRN alert for Dec 20
BioMarin Pharmaceutical, Inc. [BMRN] is up 17.79% over the past day.
Buy
82
RKLB alert for Dec 20
Rocket Lab Corp. [RKLB] is up 17.72% over the past day.
THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS
Show me the best stock
